Silence Therapeutics PLC (LON:SLN) chief executive Ali Mortazavi tells Proactive that 2016 was a year of “transformation...
Showing 25 of 554
Leading technical analyst Zak Mir tells the Proactive Investors Bulletin Board he is looking for the Amryt Pharmaceuticals...
Oxford Biodynamics (LON:OBD) CEO Christian Hoyer Millar and CSO Sasha Akoulitchev talk to Proactive's Andrew Scott about...
James Barder, CEO of Futura Medical PLC (LON:FUM) runs Proactive's Andrew Scott through the healthcare company's preliminary results for the year to the end of December 2016. Barder says he's particularly encouraged by the high level of commercial interest from potential licensing partners in their breakthrough...
Neil Murray, chief executive at Redx Pharma Plc (LON:REDX), ran through with Proactive the company's full year results to the end of September as well as outlining plans to refocus the business to concentrate on key assets in oncology and immunology - namely Porcupine and BTK.
Dr George Adams, CEO & president of VentriPoint Diagnostics (CVE:VPT) runs Proactive through the company's heart analysis technology and growth strategy as well as plans for 2017.
Ergomed's (LON:ERGO) chief business officer Andrew Mackie and Ben Nichols, CEO of subsidiary Haemostatix spoke to Proactive's Andrew Scott about the start of recruiting for a phase IIb proof-of-concept study on Peprostat - which will be used to treat a surgical complication called intraoperative bleeding.
Shaun Chilton, chief executive at Clinigen Group PLC (LON:CLIN), told Proactive he was very happy with the firm's latest half year. The specialty pharma group confirmed that underlying profits [adjusted EBITDA] rose 34% to £30mln in the half year to end December on revenues of £131mln (£156mln) "I think it's a strong...
Doug Doerfler, chief executive of MaxCyte, runs through the firm's first commercial licence deal in the gene-editing space. Under the deal, CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology. CRISPR...
Chris Claxton, Vice President of Investor Relations and Corporate Communications at Horizon Discovery Group PLC (LON:HZD) talks to Proactive about the company entering into an agreement with an unnamed global molecular diagnostics provider to develop reference standards for non-invasive prenatal testing (NIPT).
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) talks to Proactive about the company's £4.1mln raise from investors after an oversubscribed placing. The new cash infusion is to be used to strengthen its balance sheet as negotiations take place with potential commercial partners for its flagship drug, Lupuzor.
Richard Marsden, chief executive at Synairgen (LON:SNG) discusses the further positive data from its LOXL2 inhibitor programme against the lung disease IPF.
Cameron Reynolds, chief executive at blood-based diagnostic tests company VolitionRx (NYSEMKT:VNRX), discusses the group's full-year results with Proactive Investors.
Chief executive of Clinigen Group PLC (LON:CLIN) Shaun Chilton explains the significance of the firm's approval for perampanel, a treatment for seizures associated with epilepsy. "This is the first new anti-epileptic to be approved in South Africa for quite a number of years," he told Proactive's Charlotte Kan, adding...
James Barder, chief executive officer at Futura Medical (LON:FUM) discusses the Ipsos findings that show its treatment for erectile dysfunction has the potential to be a US$1bn drug.
Amryt Pharma PLC (LON:AMYT) chief executive Joe Wiley tells Proactive they'll soon begin a phase III clinical trial on a drug for people with a rare skin disorder following the completion of discussions with the US Food & Drug Administration and European Medicines Agency over the design of the study.
CEO of Clinigen PLC (LON:CLIN) Shaun Chilton talks to Proactive about the UK Pharma group making the breast cancer drug Halaven (eribulin) available in South Africa for the first time for women in an advanced stage of the disease.
ITUS Corporation CEO Robert Berman presents at Biotech Capital Conference
Sphere Medical's Richard Wright Presents to Investors at the Biotech Capital Conference
Tim Mitchell updates investors on progress at Sareum Holdings at the Biotech Capital Conference
Tissue Regenix CEO Antony Odell Presents at Biotech Capital Conference
MiMedx's Mark Landy Presents at the Biotech Capital Conference
Realm Therapeutics CEO Alex Martin presents to investors at the Biotech Capital Conference
ImmuPharma Chairman presents to investors at the Biotech Capital Conference
Wolfgang Rencken, chief executive of the point-of-care monitors and diagnostic devices company Sphere Medical Holding PLC (LON:SPHR), tells Proactive they've narrowed their losses last year as their Proxima 4 blood gases monitors gain traction. The group posted a total post-tax loss of £4.5mln for the 12 months to 31...